Yet Another Biotech Making Major Moves

Yet Another Biotech Making Major Moves

By: Dylan Sikes – News

Thursday, September 22, 2022

It’s safe to say that biotech has been absolutely dominating the headline space, as far as small and micro caps are concerned. Earlier today we discussed Spero Therapeutics Inc.'s (Nasdaq:SPRO) strong premarket action, but now looking back the session, there was another biotech company that turned heads on Thursday; Inventiva S.A. (Nasdaq:IVA).

Inventiva SA is a France-based biopharmaceutical company specialized in developing drugs that impact on nuclear receptors, transcription factors and epigenetic modulation. The company is focused on developing its product candidate, lanifibranor, for the treatment of patients with non-alcoholic steatohepatitis, or NASH, a disease for which there are currently no approved therapies. The company is also involved in developing a portfolio of pre-clinical therapy programs. It operates in the segment of Service delivery and clinical stage research, notably into therapies in the areas of oncology, fibrosis, and rare diseases. All the company's operations are in France. Most of the group's revenue is derived from its research partnerships with AbbVie and BI.

Inventiva S.A. ADRs soared on Thursday after the company announced that it signed a licensing and collaboration agreement with Chia tai-Tianqing Pharmaceutical Group Co. to develop and commercialize lanifibranor, Inventiva’s proprietary compound. Traders pushed shares up to $4.91/share (+24.94%) at the session high. 

Copyright © 2022 All rights reserved. Republication or redistribution of's content is expressly prohibited without the prior written consent of shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Other Penny Stock Movers

Telcom Innovator Receives New Order
Shares of Lithium Development Company Pop After Investment from Canadian Government
U.S. Consumer Sentiment Fell Again in November But Exceeds Expectations
Most Popular
FREE Newsletter

Back to Top